【2018年最新整理】HIVH合并肝炎.pptVIP

Patients with cirrhosis The sustained control of HBV replication in patients with cirrhosis is critical to prevent liver decompensation, hepatocellular carcinoma and death. Compliance to therapy and prevention of resistance are major. Therefore, patients with cirrhosis should be treated with combination therapy. In addition, cirrhotic patients with high serum HBV DNA and low CD4 cell count are at risk of severe hepatitis related to immune reconstitution after HAART initiation. In this situation, the use of combination anti-HBV therapy (TDF+LAM or FTC) first to reduce serum HBV before adding the third anti-retroviral drug may be an option. This strategy need to be confirmed. 　　　Among the subjects with no virologic response at week 24, 45 of 57 subjects in the group given interferon and ribavirin (79 percent) underwent liver biopsy, as did 26 of 37 subjects in the group given peginterferon and ribavirin (70 percent). A histologic response was observed in 25 of these 71 subjects (35 percent), 36 percent of such subjects in the group given interferon and ribavirin and 35 percent of such subjects in the group given peginterferon and ribavirin. The magnitude of the reduction in HCV RNA levels among subjects with a histologic response did not differ from that among those without a histologic response, indicating that a partial virologic response did not predict histologic improvement. 　　　Among the 39 subjects with a virologic response at week 24, 27 underwent a biopsy at week 48. Fourteen of these 27 subjects (52 percent) had a histologic improvement, 11 (41 percent) had no change, and 2 (7 percent) had worsening disease Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for 目前的问题Chronic Hepatitis C in HIV-Coinfected Persons 治疗影响的变量 Unfortunately, there is no noninvasive test that accurately predicts either the degree of injury seen on liver biopsy or subsequent clinical events, although elastography, a measure of liver stiffness, in combinati